|
1
|
Nieuwenhof H, Avoort I and Hullu J: Review
of squamous premalignant vulvar lesions. Crit Rev Oncol Hematol.
68:131–156. 2008.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ruan L, Xie Z, Wang H, Jiang J, Shi H and
Xu J: High-intensity focused ultrasound treatment for
non-neoplastic epithelial disorders of the vulva. Int J Gynecol
Obstet. 109:167–170. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pu D and Hou M: Etiology and pathogenesis
of white lesions of the vulva. J Practical Obstetrics Gynecol.
19:2–3. 2003.(In Chinese).
|
|
4
|
Li GT, Cao JH and Fu YJ: Expression of
cyclin D1 and p16 protein in vulvar white lesion. Zhonghua Fu Chan
Ke Za Zhi. 41:322–325. 2006.PubMed/NCBI(In Chinese).
|
|
5
|
Bantie L, Tadesse S, Likisa J, Yu M, Noll
B, Heinemann G, Lokman NA, Ricciardelli C, Oehler MK, Beck A, et
al: A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo
and in vivo efficacy against ovarian cancer. Gynecol Oncol.
159:827–838. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Le J: Gynecology and Obstetrics (7th
edition). People's Health Publishing House. 231-235:2008.(In
Chinese).
|
|
7
|
Hartwell L H, Culotti J, Pringle JR and
Reid BJ: Genetic control of the cell division cycle in yeast: A
model to account for the order of cell cycle events is deduced from
the phenotypes of yeast mutants. Science. 183:46–51. 1974.
|
|
8
|
Frederick TJ and Wood TL: IGF-I and FGF-2
coordinately enhance cyclin D1 and cyclin E-cdk2 association and
activity to promote G1 progression in oligodendrocyte progenitor
cells. Mol Cell Neurosci. 25:480–492. 2004.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Du Q, Guo X, Wang M, Li Y, Sun X and Li Q:
The application and prospect of CDK4/6 inhibitors in malignant
solid tumors. J Hematol Oncol. 13(41)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Qie S and Diehl JA: Cyclin D degradation
by E3 ligases in cancer progression and treatment. Semin Cancer
Biol. 67:159–170. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Billard-Sandu C, Tao YG, Sablin MP,
Dumitrescu G, Billard D and Deutsch E: CDK4/6 inhibitors in
P16/HPV16-negative squamous cell carcinoma of the head and neck.
Eur Arch Otorhinolaryngol. 277:1273–1280. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Deng L, Xu M, Fu L, Du G and Wang L:
Effects of CDK4/6 inhibitor palbociclib on proliferation, cell
cycle and apoptosis of human melanoma cells. Tumor. 40:521–530.
2020.(In Chinese).
|
|
13
|
Liu J, Peng Y and Wei W: Cell cycle on the
crossroad of tumorigenesis and cancer therapy. Trends Cell Biol.
32:30–44. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bury M, Le Calvé B, Ferbeyre G, Blank V
and Lessard F: New insights into CDK regulators: Novel
opportunities for cancer therapy. Trends Cell Biol. 31:331–344.
2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Janumyan Y, Cui Q, Yan L, Sansam CG,
Valentin M and Yang E: G0 function of BCL2 and BCL-xL requires BAX,
BAK, and p27 phosphorylation by mirk, revealing a novel role of BAX
and BAK in quiescence regulation. J Biol Chem. 283:34108–34120.
2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lee S, Kim S, Chung H, Moon JH, Kang SJ
and Park CG: Mesenchymal stem cell-derived exosomes suppress
proliferation of T cells by inducing cell cycle arrest through
p27kip1/Cdk2 signaling. Immunol Lett. 225:16–22. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kalu NN and Johnson FM: Do CDK4/6
inhibitors have potential as targeted therapeutics for squamous
cell cancers? Expert Opin Investig Drugs. 26:207–217.
2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhou J, Wu Z, Wong G, Pectasides E,
Nagaraja A, Stachler M, Zhang H, Chen T, Zhang H, Liu JB, et al:
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in
oesophageal squamous cell carcinoma. Nat Commun.
8(13897)2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Fang L, Xu X, Zheng W, Wu L and Wan H: The
expression of microRNA-340 and cyclin D1 and its relationship with
the clinicopathological characteristics and prognosis of lung
cancer. Asian J Surg. 44:1363–1369. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Laisom A, Pukhrambam G, Shameen Y, Akoijam
N and Sen R: Immunohistochemical study on pten and cyclin D1 in
non-neoplastic and neoplastic endometrial lesions. Int J Med Biomed
Studies. 5:2021.
|
|
21
|
Thambiah LJ, Bindushree RV, Anjum A,
Pugazhendi SK, Babu L and Nair RP: Evaluating the expression of p16
and p27 in oral epithelial dysplasias and oral squamous cell
carcinoma: A diagnostic marker for carcinogenesis. J Oral
Maxillofac Pathol. 22:59–64. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kamai T, Takagi K, Asami H, Ito Y, Arai K
and Yoshidal KI: Prognostic significance of p27Kip1 and Ki-67
expression in carcinoma of the renal pelvis and ureter. BJU Int.
86:14–19. 2000.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hao S, Wu X and Li H: Expression and
significance of cyclin D1 in vulvar carcinogenesis. China Modern
Doctor. 47:15–16. 2009.(In Chinese).
|
|
24
|
Yanagi T, Hata H, Mizuno E, Kitamura S,
Imafuku K, Nakazato S, Wang L, Nishihara H, Tanaka S and Shimizu H:
PCTAIRE1/CDK16/PCTK1 is overexpressed in cutaneous squamous cell
carcinoma and regulates p27 stability and cell cycle. J Dermatol
Sci. 86:149–157. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Shi X, Zhu K, Ye Z and Yue J: VCP/p97
targets the nuclear export and degradation of p27Kip1 during G1 to
S phase transition. FASEB J. 34:5193–5207. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Li Y, Xiao X, Chen H, Chen Z, Hu K and Yin
D: Transcription factor NFYA promotes G1/S cell cycle transition
and cell proliferation by transactivating cyclin D1 and CDK4 in
clear cell renal cell carcinoma. Am J Cancer Res. 10:2446–2463.
2020.PubMed/NCBI
|
|
27
|
Zhou L, Liu R, Liang X, Zhang S, Bi W,
Yang M, He Y, Jin J, Li S, Yang X, et al: lncRNA RP11-624L4.1 is
associated with unfavorable prognosis and promotes proliferation
via the CDK4/6-cyclin D1-Rb-E2F1 pathway in NPC. Mol Ther Nucleic
Acids. 22:1025–1039. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nawroth R, Koch J, Mantwill K, Hindupuhr S
and Holm PS: CDK4/6 inhibitors improve therapy of oncolytic
adenovirus by manipulation of RB-E2F regulated transcription.
Urologic Oncol. 38:908–909. 2020.
|
|
29
|
Li W, Li Y, Wang Z, Ren H, Zhang Y, Yang
P, Pan S and Wang Y: Genistein promotes the proliferation of
ovarian cancer OVCAR-5 cells by upregulating cyclin D1 and CDK4
expressions. J Xian Jiaotong University (Medical Sciences).
42:59–64. 2021.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
30
|
Kagawa Y, Yoshida K, Hirai T and Toge T:
Significance of the expression of p27Kip1 in esophageal squamous
cell carcinomas. Dis Esophagus. 13:179–184. 2000.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zamparelli A, Masciullo V, Bovicelli A,
Santini D, Ferrandina G, Minimo C, Terzano P, Costa S, Cinti C,
Ceccarelli C, et al: Expression of cell-cycle -associated proteins
pRB2/p130 and p27kip in vulvar squamous cell carcinomas. Hum
Pathol. 32:4–9. 2001.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zannoni GF, Faraglia B, Tarquini E,
Camerini A, Vrijens K, Migaldi M, Cittadini A and Sgambato A:
Expression of the CDK inhibitor p27kip1 and oxidative DNA damage in
non-neoplastic and neoplastic vulvar epithelial lesions. Mod
Pathol. 19:504–513. 2006.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Pu D, Yin L, Hu F and Li N: DNA content,
PCNA and P53 expression vulve lichen sclerosus and their relation
with cell proliferation. Chinese J Histochem Cytochem. 2:169–173.
2001.(In Chinese).
|
|
34
|
Liu H, Xue X, Su B and Zhang X: Expression
and significance of EGFR a and anti-oncogene protein p53 in vulva
dystrophy and carcinoma of old women. China J Modern Med. 7:4–7.
2004.(In Chinese).
|
